$MO · ALTRIA GROUP, INC.
Altria reported Q3 FY2026 results with adjusted diluted EPS of $1.52 (+4.8% YoY) on revenues net of excise taxes of $5.4 billion (+3.6% YoY). The company raised full-year 2026 adjusted EPS guidance to $5.66–$5.74, representing 4.5%–6.0% growth. The Board also authorized a $1 billion expansion of the existing share repurchase program, now expiring December 31, 2027.
- Q3 adjusted diluted EPS of $1.52 beat prior-year $1.45, up 4.8% YoY.
- FY2026 adjusted EPS guidance raised to $5.66–$5.74, implying 4.5%–6.0% growth from $5.42 base.
- Board authorized a $1 billion expansion of the share repurchase program, now expiring December 31, 2027.
- Q3 revenues net of excise taxes rose 3.6% to $5.4 billion; smokeable products OCI grew 3.8% to $3.05 billion.
- Oral tobacco OCI fell 5.4% to $434 million; nine-month oral OCI down 10.1% to $1.25 billion.
Extended-hours trading shows shares at $74.20, up +1.67% vs the $72.98 regular close, reflecting positive reception to the guidance raise and buyback expansion. The $121.86B market cap limits percentage upside but the after-hours move signals approval of the capital-return story.
Altria pairs a guidance raise with a $1B buyback expansion, reinforcing its capital-return thesis while the smoke-free transition remains a work in progress.
Altria's smokeable segment continues to fund the smoke-free pivot, with Marlboro maintaining premium share via Cowboy Cut and Basic gaining in discount — a dual-tier strategy that peers like BAT and PMI are also pursuing amid secular volume declines.
Guidance contemplates that NJOY ACE does not return to the marketplace in 2026 and assumes moderated e-vapor industry growth. Oral tobacco segment OCI declined 10.1% year-to-date, signaling ongoing pressure in the smoke-free transition.